



iSonea Adds Dr. David Dantzker to Board of Directors

“Leading pulmonologist and venture capitalist deepens iSonea’s extensive medical technology management experience”

Melbourne, Australia and Severna Park, MD — March 20, 2012

Medical technology company [iSonea Ltd.](#) (ASX: ISN; OTCQX: ISOAY) has appointed a respected pulmonologist and venture capitalist to its Board of Directors.

Dr David R. Dantzker, M.D., general partner at [Wheatley Partners, LP](#), and former Chairman of Pulmonary Disease for the American Board of Internal Medicine, has accepted the post and brings more than 10 years of medical technology portfolio management and corporate board experience to iSonea.

As a general partner at Wheatley Partners, Dr. Dantzker manages the medical technology portfolio of investments for the US-based \$250 million venture capital fund. Dr. Dantzker also brings extensive pulmonary medicine experience to iSonea’s BOD. Before joining Wheatley Partners, Dr. Dantzker held several executive positions at some of the country’s most prestigious medical institutions, including president of North Shore-Long Island Jewish Health System; vice chairman of the Department of Internal Medicine and director of the Pulmonary and Critical Care Medicine division at the University of Texas Health Science Center; and chairman of the American Board of Internal Medicine as well as its subspecialty board on Pulmonary Disease. He has authored 68 peer reviewed articles and edited five books.

“I am delighted to join iSonea’s board of directors as the company pursues its mission to develop devices and mobile health applications to help consumers take control of their own health,” said Dr. Dantzker. “By enabling the daily monitoring of one’s symptoms, iSonea both empowers patients and provides physicians with unique insight to improve the ongoing management of costly and potentially harmful respiratory disorders.”

“We look forward to working with Dr. Dantzker and appreciate the experience he brings in both the business and clinical side of chronic respiratory disease management,” said Michael Thomas, chief executive officer of iSonea Ltd. “As a member of iSonea’s Board of Directors, Dr. Dantzker will provide the company with invaluable guidance as we advance our goal of providing respiratory disease patients world-wide with easy-to-use respiratory monitoring devices and applications, and strengthening the clinical evidence for the use of Acoustic Respiratory Monitoring in clinical practice and in real-life settings.”

Media Inquiries:

Mr. Michael Thomas
Chief Executive Officer
iSonea Limited
+1 410-777-5251
mthomas@iSoneaMed.com

Emma Power
Monsoon Communications
+61 0419 149 525
emmap@monsoon.com.au

Website: www.iSoneaMed.com

About iSonea Limited

iSonea Limited (ASX:ISN; OTCQX:ISOAY) is an emerging medical technology company developing innovative, non-invasive devices and mobile health apps to improve the management of chronic, costly respiratory disorders such as asthma and COPD. By leveraging iSonea's proprietary Acoustic Respiratory Monitoring™ (ARM) technology with its AsthmaSense™ mobile applications, iSonea is turning smart phones into medical devices enabling anyone, anywhere, at any time to monitor breathing distress symptoms, in order to take action. iSonea's ARM devices have been cleared for use by the U.S. Food and Drug Administration, the Australian TGA and the European Union CE.

For more information, please visit www.iSoneaMed.com.

Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward looking statements are not historical facts but rather are based on iSonea's current expectations, estimates and projections about the industry in which iSonea operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward-looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of iSonea, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. iSonea cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of iSonea only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. iSonea will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.